Rani Therapeutics
About Rani Therapeutics
Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes. They developed the RaniPill capsule, which is Rani's novel, proprietary, and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability, and bioavailability using the RaniPill capsule. Their development efforts have enabled them to construct an extensive intellectual property portfolio that they believe provides patients with a competitive advantage.
Company Metrics
- Employees: 51-100
- Monthly Visits: 5045
- Tech Stack: 14 active products
Financial Information
- Estimated Revenue: $1M to $10M
- Total Funding: 256500000 USD
- Last Funding: 45000000 USD (Post-IPO Debt)
- Funding Status: IPO
Technology Stack
Rani Therapeutics actively uses 14 products in their tech stack.
Market Presence
Industries: Biotechnology, Pharmaceutical, Therapeutics
Headquarters: San Jose, California, United States
Employees
- Svai Sanford - Chief Financial Officer (LinkedIn)
- Talat Imran - Chief Executive Officer (LinkedIn)